International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 5 , Pages 1316-1321 , 1 August 2008

Salvage Radiotherapy After Postprostatectomy Biochemical Failure: Does Pretreatment Radioimmunoscintigraphy Help Select Patients with Locally Confined Disease?

  • Stanley L. Liauw, M.D.

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL
    • Corresponding Author InformationReprint requests to: Stanley Liauw, M.D., Department of Radiation and Cellular Oncology, University of Chicago Hospitals, 5758 S. Maryland Ave., MC 9006, Chicago, IL 60637. Tel: (773) 702-6870; Fax: (773) 834-7340
    • ,
  • Ralph R. Weichselbaum, M.D.

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL
    • ,
  • Gregory P. Zagaja, M.D.

      Affiliations

    • Department of Urology, University of Chicago Pritzker School of Medicine, Chicago, IL
    • ,
  • Ashesh B. Jani, M.D.

      Affiliations

    • Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA

Received 6 October 2007 ,Revised 2 November 2007 ,Accepted 24 November 2007.

References 

  1. Jani AB, Hellman S. Early prostate cancer: Clinical decision-making. Lancet. 2003;361:1045–1053
  2. Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002;167:528–534
  3. Karakiewicz PI, Eastham JA, Graefen M, et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: Multi-institutional assessment of 5831 patients. Urology. 2005;66:1245–1250
  4. Orvieto MA, Alsikafi NF, Shalhav AL, et al. Impact of surgical margin status on long-term cancer control after radical prostatectomy. BJU Int. 2006;98:1199–1203
  5. Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol. 2004;172:910–914
  6. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325–1332
  7. Brooks JP, Albert PS, Wilder RB, et al. Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors. J Urol. 2005;174:2204–2208
  8. Buskirk SJ, Pisansky TM, Schild SE, et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: Evaluation of prognostic factors and creation of a prognostic scoring system. J Urol. 2006;176:985–990
  9. Cheung R, Kamat AM, de Crevoisier R, et al. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys. 2005;63:134–140
  10. Katz MS, Zelefsky MJ, Venkatraman ES, et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol. 2003;21:483–489
  11. King CR, Presti JC, Gill H, et al. Radiotherapy after radical prostatectomy: Does transient androgen suppression improve outcomes?. Int J Radiat Oncol Biol Phys. 2004;59:341–347
  12. MacDonald OK, Schild SE, Vora S, et al. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: Do outcomes differ?. Urology. 2004;64:760–764
  13. Maier J, Forman J, Tekyi-Mensah S, et al. Salvage radiation for a rising PSA following radical prostatectomy. Urol Oncol. 2004;22:50–56
  14. Neuhof D, Hentschel T, Bischof M, et al. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy. Int J Radiat Oncol Biol Phys. 2007;67:1411–1417
  15. Pacholke HD, Wajsman Z, Algood CB, et al. Postoperative adjuvant and salvage radiotherapy for prostate cancer: Impact on freedom from biochemical relapse and survival. Urology. 2004;64:982–986
  16. Pazona JF, Han M, Hawkins SA, et al. Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J Urol. 2005;174:1282–1286
  17. Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: Improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys. 2007;69:54–61
  18. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035–2041
  19. Warren KS, Chodak GW, See WA, et al. Are bone scans necessary in men with low prostate specific antigen levels following localized therapy?. J Urol. 2006;176:70–742006
  20. Kane CJ, Amling CL, Johnstone PA, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003;61:607–611
  21. Bander NH. Technology insight: Monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol. 2006;3:216–225
  22. Jani AB, Liauw SL, Blend MJ. The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients. Clin Med Res. 2007;5:123–131
  23. Sodee DB, Malguria N, Faulhaber P, et al. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer: The ProstaScint imaging centers. Urology. 2000;56:988–993
  24. Noz ME, Chung G, Lee BY, et al. Enhancing the utility of ProstaScint SPECT scans for patient management. J Med Syst. 2006;30:123–132
  25. Kahn D, Williams RD, Manyak MJ, et al. ProstaScint Study Group 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol. 1998;159:2041–2047
  26. Proano JM, Sodee DB, Resnick MI, et al. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy. J Urol. 2006;175:1668–1672
  27. Nagda SN, Mohideen N, Lo SS, et al. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:834–840
  28. Thomas CT, Bradshaw PT, Pollock BH, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol. 2003;21:1715–1721
  29. Wilkinson S, Chodak G. The role of 111Indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J Urol. 2004;172:133–136
  30. Jani AB, Blend MJ, Hamilton R, et al. Influence of radioimmunoscintigraphy on postprostatectomy radiotherapy treatment decision making. J Nucl Med. 2004;45:571–578
  31. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572–578
  32. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA. 2006;296:2329–2335
  33. Pisansky TM, Pollack A, Sandler HM, et al. Advanced prostate cancer and postoperative radiotherapy. JAMA. 2007;297:950–951
  34. Jani AB, Kao J. Postprostatectomy adjuvant versus salvage radiotherapy: A complication-adjusted number-needed-to-treat analysis. Cancer. 2005;103:1833–1842
  35. Levesque PE, Nieh PT, Zinman LN, et al. Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology. 1998;51:978–984
  36. Jani AB, Spelbring D, Hamilton R, et al. Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy. J Nucl Med. 2004;45:238–246
  37. Jani AB, Blend MJ, Hamilton R, et al. Radioimmunoscintigraphy for postprostatectomy radiotherapy: Analysis of toxicity and biochemical control. J Nucl Med. 2004;45:1315–1322
  38. Sella T, Schwartz LH, Swindle PW, et al. Suspected local recurrence after radical prostatectomy: Endorectal coil MR imaging. Radiology. 2004;231:379–385
  39. Choi YJ, Kim JK, Kim N, et al. Functional MR imaging of prostate cancer. Radiographics. 2007;27:63–77
  40. Sandblom G, Sorensen J, Lundin N, et al. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology. 2006;67:996–1000
  41. Vees H, Buchegger F, Albrecht S, et al. 18F-choline and/or 11C-acetate positron emission tomography: Detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int. 2007;99:1415–1420
  42. Hricak H, Choyke PL, Eberhardt SC, et al. Imaging prostate cancer: A multidisciplinary perspective. Radiology. 2007;243:28–53
  43. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491–2499

 Presented in part at the 2007 Multidisciplinary Prostate Cancer Symposium, Orlando, FL, February 21–24, 2007.

 Conflict of interest: none.

PII: S0360-3016(07)04678-0

doi: 10.1016/j.ijrobp.2007.11.053

International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 5 , Pages 1316-1321 , 1 August 2008

Article Tools

* Image Usage & Resolution